Trials / Recruiting
RecruitingNCT07156045
Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer
Clinical Study on the Safety and Efficacy of Anti-PSMA CAR NK Cells in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
At present, no cell drug with an indication for mCRPC has been approved for marketing in China, and there is no scholar to fight against it PSMA-CAR-NK cell therapy CRPC was reported in a study. Based on the previous basic research, our company has developed CAR-NK cell injection, hoping to further evaluate its safety, tolerability and preliminary efficacy in the treatment of mCRPC patients in clinical studies, and provide new possibilities for the selection of clinical treatment strategies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-PSMA CAR-NK | Targeting PSMA CAR-NK cells |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2025-09-04
- Last updated
- 2026-01-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07156045. Inclusion in this directory is not an endorsement.